Ken Keller, Head of Oncology Business Unit
The Oncology Business Unit (OBU) is committed to achieving Daiichi Sankyo’s 2030 Vision to become an innovative global healthcare company contributing to the sustainable development of society. By aligning our U.S. and European oncology businesses and global oncology functions together under the new OBU in April 2021, we are now one unified team singularly devoted to people with cancer. As we look to become a top leader in oncology – we will do so by aiming to launch our three lead ADCs across a dozen indications in 30 countries potentially benefitting more than 50,000 people worldwide by 2025.
The field of oncology moves fast; our OBU will allow Daiichi Sankyo to move at the speed the oncology field innovates; accelerating our decision making and increasing our agility to respond to the rapid changes we see in standards of care, treatment and diagnoses patterns, and payer dynamics, ultimately making us well positioned to realize the 2030 Vision. Together, and in collaboration with the rest of the organization, the OBU will bring an unprecedented focus to the delivery of our oncology medicines to patients around the world.
Achieving our long-term 2030 Vision and contributing to sustainable growth requires us to work collaboratively within the OBU as well as across the organization to deliver on Daiichi Sankyo’s global ambition to bring life-changing medicines to patients, customers and society overall. Our ADC pipeline has the potential to transform the current standard of care across multiple types of cancer, including breast, lung, colorectal, gastric and more. We know the needs of the oncology community continue to rapidly change from diagnosis patterns to standards of care. We must continue to evolve and adapt – operating with agility and simplicity – to deliver for our patients and customers.
Daiichi Sankyo's Mission and Vision
Daiichi Sankyo's Global Operation
